USV Launches Empagliflozin Range Under Xenia Brand - Video
|
Overview
USV Pvt. Ltd., a leader in diabetes care, has announced the launch of its Xenia brand range in India, following the patent expiry of Empagliflozin.
The Xenia range includes five key products: Xenia 10 and Xenia 25 as monotherapies, Xenia M 12.5/500 and Xenia M 12.5/1000 ER with Metformin, and Xenia ST 25 combined with Sitagliptin.
Priced competitively, Xenia aims to make advanced diabetes care affordable.
- Xenia 10, containing Empagliflozin 10 mg, is priced at ₹12.5 per tablet.
- Xenia 25, containing Empagliflozin 25 mg, is priced at ₹16.39 per tablet.
- Xenia M 12.5/500, combining Empagliflozin 12.5 mg + Metformin 500 mg, is priced at ₹14 per tablet.
- Xenia M 12.5/1000 ER, combining Empagliflozin 12.5 mg + Metformin 1000 mg ER, is priced at ₹16.5 per tablet.
- Xenia ST 25, a fixed-dose combination of Empagliflozin 25 mg + Sitagliptin 100 mg, is priced at ₹22.02 per tablet.
The Xenia range is available across India, including on e-pharmacies.
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751